

Lymphoma Canada

Accomplishments

Bi-Annual Report 2022



LYMPHOMA
CANADA

A MESSAGE FROM LYMPHOMA CANADA

It is thanks to the most generous, continued, and vital support from our volunteers, Board of Directors, Scientific and Nurse Advisory Boards, our Patient Family and Caregiver Committee, funders, and donors that we are able to accomplish what we do. Hereunder please find a summary of our impact in the first six months of 2022.

We are proud to continue to drive our mission forward and to empower patients and the lymphoma community through education, support, advocacy and research.

OUR VISION

*Life Unlimited by
Lymphoma*

2022 ACCOMPLISHMENTS (JAN-JUN)



EDUCATION

- ❖ As part of our ongoing goal to keep patients and caregivers apprised of disease and treatment related updates, we hosted the following educational sessions thus far in 2022: *Watch & Wait for Lymphoma; Caregivers – How to Help Yourself and the Patient; Support and Self-Evaluation; American Society of Hematology (ASH) Update; Immune Responses in Lymphoma/CLL Patients; Understanding and Accessing Integrative Cancer Care; and CAR-T in Nova Scotia;*
- ❖ We have disseminated, free of charge, over 3,400 resources to date in 2022; we are happy to have added 18 new cancer centres in Canada to our distribution list.
- ❖ Released our Side Effect Guide which provides information on the short, long and late-term side effects of lymphoma treatments.
- ❖ Updated our Watch & Wait Guide to include all indolent lymphomas - to be released in August 2022



SUPPORT

- ❖ Lymphoma Canada, in collaboration with Wellspring, continue to facilitate monthly support groups (virtual) for lymphoma patients.
- ❖ We provide ongoing, one-on-one information and support to patients and caregivers through direct contact (phone and email).

ADVOCACY



- ❖ Completed the Frontline National Treatment Guidelines for Chronic Lymphocytic Leukemia – soon to be published; we continue to work on the Relapsed/Refractory National Treatment Guidelines for Chronic Lymphocytic Leukemia;
- ❖ Re-launched for the third year, the Molecular Testing Campaign
- ❖ Alongside our Scientific Advisory Board, a Mantle Cell lymphoma patient and caregiver, Lymphoma Canada advocated for access to CAR-T therapy for Mantle Cell Lymphoma patients. This included letters sent to all provincial and territorial ministers of health, and cancer centres. These letters were followed-up with a “Consequences of Delayed Access” email.
- ❖ Advocated to NACI and the Public Health Agency of Canada for the definition of immunocompromised to be updated to include all blood cancer patients irrespective of where they are in their treatment course. This advocacy was done in collaboration with CLL Canada and Leukemia and Lymphoma Society of Canada. We are thrilled to announce that effective June 3, the Canadian Immunization Guide was amended to include “immunocompromised due to hematologic malignancies or treatments for these conditions.”
- ❖ Participated in all patient submission opportunities with respect to lymphoma and CLL therapies to CADTH and INESSS.



RESEARCH

We received several excellent research award applications in 2022. The 2022 Lymphoma Canada Research Award Review Committee has completed its analysis of applicants and related projects. Our announcement with respect to successful applicants will be released in August 2022. We would like to thank and acknowledge all applicants for their well thought out submissions.

ONGOING AND UPCOMING STRATEGIC PRIORITIES

EDUCATION

- ❖ 6th Annual National Patient Conference (Virtual) – October 18-20th, 2022
- ❖ Upcoming educational webinars and education series on topics including: *What are Biomarkers and Why are they Important?* *Lymphoma in the Adolescent and Young Adult Population*
- ❖ New Resources! Including a Referral Algorithm to be used by general practitioners in the diagnosis of lymphoma patients; increasing GP awareness about critical signs and symptoms of lymphoma.

SUPPORT

- ❖ Stay tuned – redevelopment, rebranding and repromotion of Lymphoma Canada’s peer mentorship program!

ADVOCACY

- ❖ Planned completion and publication of the CLL National Treatment Guidelines
- ❖ Development of the Hodgkin Lymphoma National Treatment Guidelines
- ❖ Continued participation in 100% of all new lymphoma therapy CADTH/INESSS submissions
- ❖ Advocacy campaign with respect to inequities to access of lymphoma treatments in Canada

Why we do what we do...

“You have no idea how much I appreciate Lymphoma Canada’s assistance. You are an amazing valuable resource and sounding board and that is exactly what I needed”

“Keep doing the good job that Lymphoma Canada is doing”

“Nobody has helped me the way you (Lymphoma Canada) have. Just being able to talk to you and sort through next steps and how to speak with the medical staff is a huge help”



LYMPHOMA
CANADA

6860 Century Avenue, Suite 202
Mississauga, ON L5N 2W5

Toll free: 1-866-659-5556
General Inquiries: info@lymphoma.ca
Website: lymphoma.ca

Charitable Registration Number
87346 1040 RR0001